NMTC icon

NeuroOne Medical Technologies

0.5740 USD
+0.0091
1.61%
At close Jun 12, 4:00 PM EDT
After hours
0.5700
-0.0040
0.70%
1 day
1.61%
5 days
0.23%
1 month
-7.84%
3 months
-39.74%
6 months
-24.84%
Year to date
-30.41%
1 year
-36.92%
5 years
-92.07%
10 years
-92.07%
 

About: NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.

Employees: 17

0
Funds holding %
of 7,295 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

3,050% more call options, than puts

Call options by funds: $63K | Put options by funds: $2K

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

23% more capital invested

Capital invested by funds: $1.34M [Q4 2024] → $1.64M (+$304K) [Q1 2025]

1.0% more ownership

Funds ownership: 5.25% [Q4 2024] → 6.25% (+1.0%) [Q1 2025]

10% less funds holding

Funds holding: 20 [Q4 2024] → 18 (-2) [Q1 2025]

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$1.45
153%
upside
Avg. target
$1.45
153%
upside
High target
$1.45
153%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Ladenburg Thalmann
Jeff Cohen
153%upside
$1.45
Buy
Initiated
5 May 2025

Financial journalist opinion

Neutral
GlobeNewsWire
1 week ago
NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary
EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary.
NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary
Neutral
GlobeNewsWire
2 weeks ago
NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025
EDEN PRAIRIE, Minn., May 29, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the MedInvest MedTech, AI and Digital Health Conference taking place in San Francisco, CA on June 3-4, 2025.
NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025
Neutral
Seeking Alpha
1 month ago
NeuroOne Medical Technologies Corporation (NMTC) Q2 2025 Earnings Call Transcript
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q2 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Dave Rosa – CEO Ron McClurg – CFO Chris Volker - COO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Good day, ladies and gentlemen. Welcome to the Second Quarter of Fiscal Year 2025 Financial Results Conference Call for NeuroOne Medical Technologies Corporation.
NeuroOne Medical Technologies Corporation (NMTC) Q2 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%
Filed 510(k)Submission with FDA for OneRF ® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule
NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%
Neutral
GlobeNewsWire
1 month ago
NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor
Significant Neurological  Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies
NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor
Neutral
Newsfile Corp
1 month ago
NeuroOne Medical Announces Participation in The D. Boral Capital Inaugural Global Conference
Eden Prairie, Minnesota--(Newsfile Corp. - May 5, 2025) - NeuroOne Medical (NASDAQ: NMTC), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.
NeuroOne Medical Announces Participation in The D. Boral Capital Inaugural Global Conference
Neutral
GlobeNewsWire
1 month ago
NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time
EDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2025, before market open on May 13, 2025.
NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time
Neutral
GlobeNewsWire
1 month ago
NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
Multi-Contact Probe Provides Alternative to Pharmaceutical and Invasive Surgical Treatments Submission Completed Earlier Than Anticipated EDEN PRAIRIE, Minn., April 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous guidance.
NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
Neutral
GlobeNewsWire
1 month ago
NeuroOne® Issues Letter to Shareholders
Company Now Fully Funded Through at least Fiscal 2026; Company Confirms No Material Impact from Global Tariffs EDEN PRAIRIE, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has issued a letter to shareholders from CEO, Dave Rosa.
NeuroOne® Issues Letter to Shareholders
Neutral
GlobeNewsWire
1 month ago
NeuroOne® OneRF® Technology Success Story Featured on Fox News
Pediatric Patient Treated with OneRF® Ablation System Goes From Up to 10 Nightly Seizures to Zero EDEN PRAIRIE, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that its proprietary OneRF® Ablation System was recently featured in a national Fox News article highlighting the successful treatment of a pediatric epilepsy patient.
NeuroOne® OneRF® Technology Success Story Featured on Fox News
Charts implemented using Lightweight Charts™